A pharmacometric approach to evaluate drugs for potential repurposing as COVID-19 therapeutics
Issued Date
2022-01-01
Resource Type
ISSN
17512433
eISSN
17512441
Scopus ID
2-s2.0-85137347503
Pubmed ID
36017624
Journal Title
Expert Review of Clinical Pharmacology
Volume
15
Issue
8
Start Page
945
End Page
958
Rights Holder(s)
SCOPUS
Bibliographic Citation
Expert Review of Clinical Pharmacology Vol.15 No.8 (2022) , 945-958
Suggested Citation
Wattanakul T., Chotsiri P., Scandale I., Hoglund R.M., Tarning J. A pharmacometric approach to evaluate drugs for potential repurposing as COVID-19 therapeutics. Expert Review of Clinical Pharmacology Vol.15 No.8 (2022) , 945-958. 958. doi:10.1080/17512433.2022.2113388 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/86293
Title
A pharmacometric approach to evaluate drugs for potential repurposing as COVID-19 therapeutics
Other Contributor(s)
Abstract
Introduction: Developing and evaluating novel compounds for treatment or prophylaxis of emerging infectious diseases is costly and time-consuming. Repurposing of already available marketed compounds is an appealing option as they already have an established safety profile. This approach could substantially reduce cost and time required to make effective treatments available to fight the COVID-19 pandemic. However, this approach is challenging since many drug candidates show efficacy in in vitro experiments, but fail to deliver effect when evaluated in clinical trials. Better approaches to evaluate in vitro data are needed, in order to prioritize drugs for repurposing. Areas covered: This article evaluates potential drugs that might be of interest for repurposing in the treatment of patients with COVID-19 disease. A pharmacometric simulation-based approach was developed to evaluate in vitro activity data in combination with expected clinical drug exposure, in order to evaluate the likelihood of achieving effective concentrations in patients. Expert opinion: The presented pharmacometric approach bridges in vitro activity data to clinically expected drug exposures, and could therefore be a useful compliment to other methods in order to prioritize repurposed drugs for evaluation in prospective randomized controlled clinical trials.